Protara Therapeutics (TARA)

Executive Summary

Protara Therapeutics (NASDAQ: TARA) is a clinical-stage biopharmaceutical company developing cell therapies and targeted immunotherapies for cancer and rare diseases. Its lead candidate, TARA-002, is being evaluated in non-muscle invasive bladder cancer (NMIBC) across Phase 1b (completed), Phase 2 (recruiting), and a pivotal Phase 3 trial (initiating May 2026). TARA-002 is also in a Phase 2 study for lymphatic malformations, with data expected by mid-2026. Additionally, the company is advancing IV Choline Chloride in a Phase 2/3 trial for choline deficiency and liver injury associated with long-term parenteral nutrition. With multiple near-term catalysts, including Phase 3 initiation and Phase 2 readouts, Protara is poised to deliver key value-driving milestones over the next 12 months.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 initiation of TARA-002 in NMIBC70% success
• Q2 2026Phase 2 data readout for TARA-002 in lymphatic malformations65% success